{"text": "The United States and Moderna announced the agreement for 100 million doses of its potential COVID-19 vaccine late on Tuesday.The companys vaccine candidate, mRNA-1273, is one of the few that have already advanced to the final stage of testing.The deal confirms Modernas experimental vaccine is one of the leading contenders, said BMO analyst George Farmer, who has an outperform rating on the stock.With the U.S. contract now signed, other deals could follow, said Jefferies analyst Michael Yee, who has a buy rating.We assume other countries ... will want to secure deals out of sheer responsibility before the capacity of the major 3-4 players is locked up.Under the contract, Moderna will provide about 100 million doses, with the price coming to around $30.50 per person for a two dose regimen.SVB Leerink analyst Mani Foroohar said the price was lower than deals signed by rivals and pointed to increased competition driving down prices in the coronavirus vaccine market.The U.S. deal would pay out in full if the vaccine achieves certain regulatory milestones before Jan. 31, 2021. (bit.ly/2CjrpKr)"}